EMEA-002765-PIP01-19

Table of contents

Key facts

Invented name
Kisqali
Active substance
ribociclib succinate
Therapeutic area
Oncology
Decision number
P/0218/2020
PIP number
EMEA-002765-PIP01-19
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of breast cancer
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating